scholarly journals Serum calcium, tumor size, and hormone receptor status in women with untreated breast cancer

2012 ◽  
Vol 13 (7) ◽  
pp. 467-471 ◽  
Author(s):  
Sunn Sunn H. Thaw ◽  
Abe E. Sahmoun ◽  
Gary G. Schwartz
Keyword(s):  
Breast Cancer ◽  
Serum Calcium ◽  
Tumor Size ◽  
Hormone Receptor ◽  
Hormone Receptor Status ◽  
Receptor Status

4D radiomic biomarker of functional tumor heterogeneity to predict breast cancer recurrence in pretreatment dynamic FDG-PET.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e12573-e12573
Author(s):  
Rhea Chitalia ◽  
Varsha Viswanath ◽  
Austin R. Pantel ◽  
Lanell Peterson ◽  
Eric Cohen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Size ◽  
Hormone Receptor ◽  
Fdg Pet ◽  
Tumor Heterogeneity ◽  
Hormone Receptor Status ◽  
Receptor Status ◽  
Cancer Heterogeneity ◽  
C Statistic ◽  
Discriminatory Capacity

e12573 Background: Breast cancer heterogeneity is thought to be associated with adverse outcomes. Dynamic molecular imaging modalities, including PET, permit 4-D sampling of tumor biologic properties and can therefore capture functional heterogeneity revealed by the temporal dimension of the dynamic tracer uptake. With the goal of improved non-invasive characterization of in vivo tumor biology, we have developed and tested a novel radiomic biomarker that characterizes 4-D functional tumor heterogeneity (FTH). We hypothesize subclonal populations are spatially contiguous regions of shared physiologic behavior that drive breast cancer heterogeneity and can be quantified. We describe an initial application of this approach to FDG PET imaging of breast cancer. Methods: We retrospectively analyzed data from a study of 50 patients with locally advanced breast cancer. Patients underwent 60-minute dynamic FDG PET over the chest prior to neoadjuvant chemotherapy and breast surgery and were followed for disease recurrence (DFS). A 3-D region bounding each tumor was identified by a radiologist and a novel Markov Random Field based 4-D segmentation paradigm segmented each tumor into three spatially constrained sub-regions with distinct time activity curve dynamics. From each tumor, an FTH imaging signature was extracted characterizing cluster compactness and separation. FTH imaging signatures were z-score normalized across all patients. Time-to-event analysis was used to assess the prognostic value of the FTH imaging signatures in predicting DFS. Discriminatory capacity compared to a baseline model of established prognostic factors (age, hormone receptor status, baseline tumor size) and standard PET uptake and kinetics markers (SUV, K1, and Ki) shown to be predictive of DFS (Dunnwald, J Clin Oncol 26:4449, 2008) was evaluated using the c-statistic and the log-likelihood statistical test. Results: 17 of 50 women (34%) had recurrence events. Adding FTH imaging signatures to the baseline model of age, baseline tumor size, and hormone receptor status improved a cross validated c-statistic from 0.51 to 0.74 (p < 0.05), and demonstrated higher discriminatory capacity over a model of age, tumor size, hormone receptor status, and standard PET measures (c-statistic = 0.59). Conclusions: Imaging biomarkers of 4-D metabolic tumor heterogeneity may add prognostic value in predicting recurrence-free survival in breast cancer and merit further study.

Association of hormone receptor status with grading, age of onset, and tumor size in BRCA1-associated breast cancer

2009 ◽  
Vol 454 (5) ◽  
pp. 519-524 ◽  
Author(s):  
M. Graeser ◽  
◽  
K. Bosse ◽  
M. Brosig ◽  
C. Engel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Size ◽  
Hormone Receptor ◽  
Age Of Onset ◽  
Hormone Receptor Status ◽  
Receptor Status

A detailed analysis of the risk factors influencing local and distant breast cancer recurrence during adjuvant endocrine therapy

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 562-562
Author(s):  
J. Houghton
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Tumor Size ◽  
Hormone Receptor ◽  
Distant Recurrence ◽  
Hormone Receptor Status ◽  
Nodal Involvement ◽  
Receptor Status ◽  
Factors Influencing ◽  
The Impact

562 Background: The ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC; ISRCTN18233230 ) trial compared the efficacy and safety of 5 years’ anastrozole, tamoxifen, or combination as adjuvant therapy for 9366 postmenopausal women with early invasive breast cancer. Here, risk factors influencing local and distant recurrences during the trial, independent of trial treatment, are assessed. Methods: The influence of standard baseline factors such as hormone receptor status, nodal involvement, tumor size, grade and age were evaluated on both local and distant recurrence rates. The use of other treatments (adjuvant chemotherapy, radiotherapy) and surgical status (mastectomy and axillary surgery) were also included. In addition, weight, body mass index, hysterectomy and prior hormone- replacement therapy were added. Cox models were used to analyze events by prognostic factors, and subsequently adjusted by country, before the production of confirmatory models. Results: For both local and distant recurrence, the highest risk correlated with poorer tumor differentiation, larger tumor size, increased nodal involvement and a negative hormone receptor status (see table ). While surgical status also affected the risk of developing a recurrence, previous treatments were less important, but residence in the USA showed a significant advantage. No association was seen with hysterectomy or weight for any recurrence. Conclusions: Although the pattern of risk varied for local and distant recurrence, tumor grade, size, and nodal involvement were the strongest risk factors for both. In comparison, the impact of previous treatments on hazard risk was lower. These data from a large international clinical trial confirm that women with less differentiated or larger tumors, and those with involved nodes, are at an increased risk of recurrence. [Table: see text] [Table: see text]

Influence of comorbidity on guideline concordant care for breast cancer: Findings from the Center for Disease Control and Prevention National Program of Cancer Registry (NPCR) patterns of care study.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 6052-6052
Author(s):  
Gretchen Genevieve Kimmick ◽  
Steven Fleming ◽  
Susan A Sabatino ◽  
Xiao-cheng Wu ◽  
Wenke Hwang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Size ◽  
Hormone Receptor ◽  
Hormone Receptor Status ◽  
Patterns Of Care ◽  
Her2 Status ◽  
Receptor Status ◽  
Patterns Of Care Study ◽  
Comorbidity Burden ◽  
Care Study

6052 Background: Comorbidity burden predicts cancer treatment and may influence outcome. We explore the relationship of specific comorbid illnesses with receipt of guideline concordant care for early stage breast cancer. Methods: The NPCR’s Patterns of Care study reabstracted the medical records of breast cancer cases diagnosed in 2004 from 7 cancer registries. We included women with nonmetastatic in situ and invasive breast cancer, known hormone receptor status, node status, and tumor size. Guideline-concordant management, including surgery, radiation, chemotherapy and endocrine components, was based on NCCN guidelines using tumor size, nodal and hormone receptor status. Comorbidity was measured according to the Adult Comorbidity Evaluation Index (ACE). Multivariate logistic regression models were used to determine factors associated with guideline-concordant care, and included overall ACE scores and 26 separate ACE comorbidity categories, as well as age, race, hormone receptor status, and HER2 status. Results: The study sample included 6904 women (mean age 58.7 and range 20-99 years, 76% white, 45% with ACE comorbidity score of 0, 70% ER and/or PR+, 13% HER2+). Overall, 64% received guideline-concordant care. Receipt of guideline-concordant care varied by overall comorbidity burden (71% for none; 65% for minor; 63% for moderate; 50% for severe; p<0.05). The presence of hypertension (OR 1.26, 95% CI 1.08-1.48) predicted receipt of guideline concordant care, whereas, peripheral artery disease (OR 0.44, 95% CI 0.21-0.93), diabetes (OR 0.78, 95% CI 0.63-0.97) and dementia (OR 0.31, 95% CI 0.13-0.74) predicted lack of guideline concordant care. Older age, black race, and hormone receptor positivity were associated with less, and HER2 positivity with receipt of more guideline-concordant care. Conclusions: Overall those with more comorbidity burden received less guideline-concordant care. However, the effects vary by specific conditions. The odds of receiving guideline-concordant care was greater in those with hypertension and less in those with peripheral arterial disease, diabetes, and dementia.

Hormone receptor status in primary breast cancer—time for a consensus?

2002 ◽  
Vol 38 (9) ◽  
pp. 1201-1203 ◽  
Author(s):  
G.C Wishart ◽  
M Gaston ◽  
A.A Poultsidis ◽  
A.D Purushotham
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Primary Breast Cancer ◽  
Hormone Receptor Status ◽  
Receptor Status

A STUDY ON HORMONE RECEPTOR STATUS IN BREAST CANCER IN RELATION TO HISTOLOGICAL GRADING, AGE AND LYMPH NODE INVOLVEMENT

2021 ◽  
pp. 41-44
Author(s):  
R. Rani Suganya ◽  
M. Annapoorani ◽  
C. Naveen Kumar
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Hormone Receptor ◽  
Histological Grade ◽  
Systemic Disease ◽  
Lymph Node Involvement ◽  
Hormone Receptor Status ◽  
Major Health Problem ◽  
Receptor Status ◽  
Node Involvement

Breast cancer is the major health problem for the women throughout the world.Management of breast cancer has evolved to include both surgery for local disease and medical therapy for systemic disease. Multiple treatment options are available depending on various factors such as histological grade, hormone receptor status etc. The aim of this study is to correlate the hormone receptor status with prognostic factors such as lymph node involvement, tumour grading and age among patients diagnosed with breast cancer in our institution. The results of this study serve to prognosticate the severity of disease among various strata of patients.

scholarly journals Is the biology of breast cancer changing? A study of hormone receptor status 1984–86 and 1996–1997

2008 ◽  
Vol 34 (10) ◽  
pp. 1172
Author(s):  
Sylvia Brown ◽  
E. Mallon ◽  
J. Edwards ◽  
F. Campbell ◽  
L. McGlynn ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Hormone Receptor Status ◽  
Receptor Status
Sign in / Sign up

Export Citation Format

Share Document